Tofacitinib Tablet, Film Coated
NDC Package 33342-541-54
Package Information
Tofacitinib tablets is tofacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis-pcJIA). This formulation utilizes a tablet, film coated delivery system. Marketed by Macleods Pharmaceuticals Limited, this product is identified by NDC 33342-541 and is authorized under FDA application ANDA219530.
Identification & Billing
- RxCUI: 1357541 - tofacitinib 5 MG Oral Tablet
- RxCUI: 1357541 - tofacitinib 5 MG (as tofacitinib citrate 8 MG) Oral Tablet
- RxCUI: 2048566 - tofacitinib 10 MG Oral Tablet
- RxCUI: 2048566 - tofacitinib 10 MG (as tofacitinib citrate 16 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 33342 - Macleods Pharmaceuticals Limited
- 33342-541 - Tofacitinib
- 33342-541-54 - 120 TABLET, FILM COATED in 1 BOTTLE
- 33342-541 - Tofacitinib
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (33342-541). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 33342-541-54 identifies a specific commercial package of 120 tablet, film coated in 1 bottle of Tofacitinib, a human prescription drug labeled by Macleods Pharmaceuticals Limited. This tablet, film coated is formulated for oral use and contains tofacitinib citrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Macleods Pharmaceuticals Limited on June 03, 2026. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Tofacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis-pcJIA). It helps to decrease pain/tenderness/swelling in the joints. Tofacitinib is also used to treat a certain bowel disease (ulcerative colitis). It helps to reduce symptoms of ulcerative colitis such as diarrhea, rectal bleeding, and stomach pain.
How is this Macleods Pharmaceuticals Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 33342054154. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.